Equity
Additional Paid-In Capital
Bristol-Myers Squibb Additional Paid-In Capital decreased by 0.0% to $46.37B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 0.8%, from $46.01B to $46.37B. Over 5 years (FY 2020 to FY 2025), Additional Paid-In Capital shows relatively stable performance with a 0.9% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementBalance Sheet Statement
SectionEquity
CategoryCapital Allocation
SignalHigher is better
VolatilityModerate
First reportedQ4 2014
Last reportedQ1 2026Apr 30, 2026
How to read this metric
An increase typically signals equity financing or the issuance of shares for employee compensation.
Detailed definition
This represents the amount of capital received from shareholders in excess of the par value of the common stock. It is g...
Peer comparison
High levels are common in growth-oriented tech companies that utilize stock-based compensation to attract talent.
Metric ID:
additional_paid_in_capitalHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $44.06B | $44.29B | $44.36B | $43.76B | $44.38B | $44.96B | $45.17B | $45.14B | $45.30B | $44.85B | $45.68B | $45.66B | $45.77B | $45.90B | $46.02B | $46.01B | $46.13B | $46.27B | $46.39B | $46.37B |
| QoQ Change | — | +0.5% | +0.2% | -1.4% | +1.4% | +1.3% | +0.5% | -0.1% | +0.4% | -1.0% | +1.9% | -0.1% | +0.2% | +0.3% | +0.3% | -0.0% | +0.3% | +0.3% | +0.3% | -0.0% |
| YoY Change | — | — | — | — | +0.7% | +1.5% | +1.8% | +3.2% | +2.1% | -0.2% | +1.1% | +1.1% | +1.0% | +2.3% | +0.7% | +0.8% | +0.8% | +0.8% | +0.8% | +0.8% |
Range$43.76B – $46.39B
CAGR+1.1%
Avg YoY Growth+1.2%
Median YoY Growth+0.9%
Additional Paid-In Capital at Other Companies
Frequently Asked Questions
- What is Bristol-Myers Squibb's additional paid-in capital?
- Bristol-Myers Squibb (BMY) reported additional paid-in capital of $46.37B in Q1 2026.
- How has Bristol-Myers Squibb's additional paid-in capital changed year-over-year?
- Bristol-Myers Squibb's additional paid-in capital increased by 0.8% year-over-year, from $46.01B to $46.37B.
- What is the long-term trend for Bristol-Myers Squibb's additional paid-in capital?
- Over 5 years (2020 to 2025), Bristol-Myers Squibb's additional paid-in capital has grown at a 0.9% compound annual growth rate (CAGR), from $44.33B to $46.39B.
- What does additional paid-in capital mean?
- Capital received from investors above the par value of the shares.